Qure.AI Technologies Inc.

Qure.AI Technologies develops FDA-cleared artificial intelligence software solutions for medical imaging interpretation and follow-up management, focused on early detection and risk stratification of lung nodules and pulmonary pathology. The platform integrates with PACS, EMR, and dictation systems to support radiologists, pulmonologists, and emergency physicians. Core offerings include qXR-LN for lung nodule detection on chest radiographs (6–10mm sensitivity), qCT LN Quant for CT-based volumetric nodule quantification with Lung-RADS and Brock score risk stratification, and qTrack for longitudinal patient follow-up management and care coordination. The company has obtained 26 FDA-cleared indications and holds 40 patents. Products address reimbursement under CMS CPT codes 0721T, 0722T, and 0727T. Qure.AI operates across 107 countries with over 200 peer-reviewed publications and abstracts. The platform serves major healthcare partners including vRad, AstraZeneca, Merck, University Hospitals Cleveland, and Sinai Chicago. The company reported $130M in capital raised and impacts 40M+ lives annually. Solutions emphasize integration into existing clinical workflows without disruption, leveraging LLM-based intelligence for contextual risk assessment beyond traditional NLP.